# AbbVie Inc. (ABBV) financials

AbbVie Inc. reported revenue of $61.2 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 8.6% from fiscal 2024. Net income was $4.23 billion and diluted earnings per share $2.36.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $17.4 billion, up 10.3% from a year earlier.

Source: AbbVie Inc.'s annual and quarterly reports, compiled and checked by AapWire. Latest report filed 3 Nov 2026. Amounts in USD. Page: https://aapwire.com/stocks/ABBV. Retrieved 2026-11-16.

## Latest results: Q3 FY2026

AbbVie Inc. reported revenue of $17.4 billion, up 10.3% from a year earlier, net income of $4.22 billion and diluted earnings per share of $2.37 against $0.10 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, the results first announced on 30 Oct 2026.

| Measure | Q3 FY2026 | Q3 FY2025 | Change |
| --- | ---: | ---: | ---: |
| Revenue | $17.40B | $15.78B | +10.3% |
| Gross profit | $13.12B | $10.47B | +25.3% |
| Gross margin | 75.4% | 66.4% | +9.0 pts |
| Operating income | $6.27B | $1.90B | +229% |
| Operating margin | 36.0% | 12.1% | +23.9 pts |
| Net income | $4.22B | $186.0M | +2168% |
| Diluted EPS | $2.37 | $0.10 | +2270% |
| Operating cash flow | $7.61B | $7.02B | +8.3% |
| Capital expenditure | $301.0M | $381.0M | −21.0% |
| Free cash flow | $7.30B | $6.64B | +10.0% |

Page: https://aapwire.com/stocks/ABBV/earnings

## Annual figures (fiscal years)

| Measure | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $25.64B | $28.22B | $32.75B | $33.27B | $45.80B | $56.20B | $58.05B | $54.32B | $56.33B | $61.16B |
| Revenue growth | +12.2% | +10.1% | +16.1% | +1.6% | +37.7% | +22.7% | +3.3% | −6.4% | +3.7% | +8.6% |
| Gross profit | $19.80B | $21.17B | $25.04B | $25.83B | $30.42B | $38.75B | $40.64B | $33.90B | $39.43B | $42.96B |
| Operating income | $9.34B | $9.54B | $6.38B | $12.98B | $11.36B | $17.92B | $18.12B | $12.76B | $9.14B | $15.07B |
| Net income | $5.95B | $5.31B | $5.69B | $7.88B | $4.62B | $11.54B | $11.84B | $4.86B | $4.28B | $4.23B |
| Diluted EPS | $3.63 | $3.30 | $3.66 | $5.28 | $2.72 | $6.45 | $6.63 | $2.72 | $2.39 | $2.36 |
| Operating cash flow | $7.04B | $9.96B | $13.43B | $13.32B | $17.59B | $22.78B | $24.94B | $22.84B | $18.81B | $19.03B |
| Capital expenditure | $479.0M | $529.0M | $638.0M | $552.0M | $798.0M | $787.0M | $695.0M | $777.0M | $974.0M | $1.21B |
| Free cash flow | $6.56B | $9.43B | $12.79B | $12.77B | $16.79B | $21.99B | $24.25B | $22.06B | $17.83B | $17.82B |
| Gross margin | 77.2% | 75.0% | 76.4% | 77.6% | 66.4% | 69.0% | 70.0% | 62.4% | 70.0% | 70.2% |
| Operating margin | 36.4% | 33.8% | 19.5% | 39.0% | 24.8% | 31.9% | 31.2% | 23.5% | 16.2% | 24.6% |
| Net margin | 23.2% | 18.8% | 17.4% | 23.7% | 10.1% | 20.5% | 20.4% | 9.0% | 7.6% | 6.9% |
| Cash and equivalents | $5.10B | $9.30B | $7.29B | $39.92B | $8.45B | $9.75B | $9.20B | $12.81B | $5.52B | $5.23B |
| Total debt | $36.84B | $37.37B | $40.31B | $67.09B | $87.06B | $77.58B | $64.19B | $60.29B | $68.02B | $68.38B |
| Shareholders' equity | $4.64B | $5.10B | −$8.45B | −$8.17B | $13.08B | $15.41B | $17.25B | $10.36B | $3.33B | −$3.27B |
| Diluted shares | 1.6B | 1.6B | 1.5B | 1.5B | 1.7B | 1.8B | 1.8B | 1.8B | 1.8B | 1.8B |
| Dividends per share | $2.35 | $2.63 | $3.95 | $4.39 | $4.84 | $5.31 | $5.71 | $5.99 | $6.29 | $6.65 |

## Quarterly figures (last eight fiscal quarters)

| Measure | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $15.10B | $13.34B | $15.42B | $15.78B | $16.62B | $15.00B | $16.99B | $17.40B |
| Revenue, year on year | +5.6% | +8.4% | +6.6% | +9.1% | +10.0% | +12.4% | +10.2% | +10.3% |
| Gross margin | 70.9% | 70.0% | 71.8% | 66.4% | 72.6% | 71.9% | 74.7% | 75.4% |
| Operating income | −$1.49B | $3.73B | $4.89B | $1.90B | $4.54B | $3.99B | $6.43B | $6.27B |
| Net income | −$22.00M | $1.29B | $938.0M | $186.0M | $1.82B | $695.0M | $3.61B | $4.22B |
| Diluted EPS | −$0.02 | $0.72 | $0.52 | $0.10 | $1.02 | $0.39 | $2.03 | $2.37 |
| Free cash flow | $6.76B | $1.40B | $4.88B | $6.64B | $4.89B | $3.56B | $3.11B | $7.30B |

## Operating KPIs

| KPI | Latest | Period | Change on a year |
| --- | ---: | --- | --- |
| [Skyrizi revenue](https://aapwire.com/stocks/ABBV/kpi/skyrizi-revenue) | $5.8B | quarter to 30 Sep 2026 | up 22.7% |
| [Rinvoq revenue](https://aapwire.com/stocks/ABBV/kpi/rinvoq-revenue) | $2.7B | quarter to 30 Sep 2026 | up 23.9% |
| [Botox Therapeutic revenue](https://aapwire.com/stocks/ABBV/kpi/botox-therapeutic-revenue) | $1.1B | quarter to 30 Sep 2026 | up 9.6% |
| [Vraylar revenue](https://aapwire.com/stocks/ABBV/kpi/vraylar-revenue) | $1.1B | quarter to 30 Sep 2026 | up 14.3% |
| [Venclexta revenue](https://aapwire.com/stocks/ABBV/kpi/venclexta-revenue) | $803.0M | quarter to 30 Sep 2026 | up 10.6% |
| [Humira revenue](https://aapwire.com/stocks/ABBV/kpi/humira-revenue) | $683.0M | quarter to 30 Sep 2026 | down 31.2% |
| [Botox Cosmetic revenue](https://aapwire.com/stocks/ABBV/kpi/botox-cosmetic-revenue) | $669.0M | quarter to 30 Sep 2026 | up 5.0% |
| [Imbruvica revenue](https://aapwire.com/stocks/ABBV/kpi/imbruvica-revenue) | $522.0M | quarter to 30 Sep 2026 | down 26.1% |
| [Ubrelvy revenue](https://aapwire.com/stocks/ABBV/kpi/ubrelvy-revenue) | $449.0M | quarter to 30 Sep 2026 | up 26.8% |
| [Qulipta revenue](https://aapwire.com/stocks/ABBV/kpi/qulipta-revenue) | $398.0M | quarter to 30 Sep 2026 | up 38.2% |
| [Creon revenue](https://aapwire.com/stocks/ABBV/kpi/creon-revenue) | $361.0M | quarter to 30 Sep 2026 | down 1.9% |
| [Vyalev revenue](https://aapwire.com/stocks/ABBV/kpi/vyalev-revenue) | $286.0M | quarter to 30 Sep 2026 | up 107.2% |
| [Mavyret revenue](https://aapwire.com/stocks/ABBV/kpi/mavyret-revenue) | $265.0M | quarter to 30 Sep 2026 | down 15.1% |
| [Elahere revenue](https://aapwire.com/stocks/ABBV/kpi/elahere-revenue) | $224.0M | quarter to 30 Sep 2026 | up 31.8% |
| [Juvederm Collection revenue](https://aapwire.com/stocks/ABBV/kpi/juvederm-collection-revenue) | $222.0M | quarter to 30 Sep 2026 | down 12.3% |
| [Linzess/Constella revenue](https://aapwire.com/stocks/ABBV/kpi/linzess-constella-revenue) | $175.0M | quarter to 31 Dec 2025 | down 24.9% |
| [Ozurdex revenue](https://aapwire.com/stocks/ABBV/kpi/ozurdex-revenue) | $128.0M | quarter to 31 Dec 2025 | up 6.7% |
| [Epkinly revenue](https://aapwire.com/stocks/ABBV/kpi/epkinly-revenue) | $108.0M | quarter to 30 Sep 2026 | up 56.5% |
| [Lumigan/Ganfort revenue](https://aapwire.com/stocks/ABBV/kpi/lumigan-ganfort-revenue) | $104.0M | quarter to 31 Dec 2025 | down 12.6% |
| [Duodopa revenue](https://aapwire.com/stocks/ABBV/kpi/duodopa-revenue) | $92.0M | quarter to 31 Dec 2025 | down 14.8% |
| [Alphagan/Combigan revenue](https://aapwire.com/stocks/ABBV/kpi/alphagan-combigan-revenue) | $54.0M | quarter to 31 Dec 2025 | down 30.8% |
| [Immunology revenue](https://aapwire.com/stocks/ABBV/kpi/immunology-revenue) | $9.2B | quarter to 30 Sep 2026 | up 16.2% |
| [Neuroscience revenue](https://aapwire.com/stocks/ABBV/kpi/neuroscience-revenue) | $3.4B | quarter to 30 Sep 2026 | up 19.3% |
| [Oncology revenue](https://aapwire.com/stocks/ABBV/kpi/oncology-revenue) | $1.7B | quarter to 30 Sep 2026 | up 0.8% |
| [Aesthetics revenue](https://aapwire.com/stocks/ABBV/kpi/aesthetics-revenue) | $1.2B | quarter to 30 Sep 2026 | down 1.4% |
| [Eye Care revenue](https://aapwire.com/stocks/ABBV/kpi/eye-care-revenue) | $580.0M | quarter to 31 Dec 2025 | down 10.2% |

## Method

Each period is read from the report the company filed and checked against accounting identities; a figure that does not pass is left blank (—), never estimated. Free cash flow is operating cash flow less capital expenditure. Diluted EPS is as the company reported it, adjusted for later stock splits. Research information only, not investment advice.
